The NHS offers a variety of free weight loss services across the UK in 2026, helping thousands tackle obesity with support and medication. From community programmes to prescription meds, this guide breaks down what’s available, who qualifies, and what to expect.

Key Figures on NHS Weight Loss Support in 2026

  • Over 1.5 million people accessed NHS weight loss support services in 2025, marking a 12% increase compared to 2023 figures.
  • NHS-funded weight management programmes are free of charge for eligible patients, typically those with a BMI of 25 or higher.
  • Medications like orlistat and liraglutide are prescribed under NHS guidelines, with liraglutide being available to patients meeting strict criteria.
  • The new GLP-1 oral medication, foundayo, approved by NICE in late 2025, isn't yet routinely available on the NHS in 2026 due to ongoing funding reviews.
  • Typical NHS weight loss programme durations range between 12 to 26 weeks, with some extended support for complex cases.
  • Referral to Tier 3 specialist services requires a BMI of 30 or above, or 27.5 with obesity-related comorbidities such as type 2 diabetes, hypertension, or sleep apnoea.
  • Waiting times for NHS weight loss services vary regionally but average around 6 to 10 weeks, with longer delays in areas like the North East and Wales.
  • Private sector weight loss medication costs range from £100 to £300 per month, significantly higher than NHS prescriptions which cost a standard £9.35 per item as of 2026.
  • The NHS spends approximately £320 million annually on obesity-related services, including prevention, treatment, and post-intervention support.
  • 70% of NHS patients using weight loss medication report significant weight reduction (over 5% body weight) after 6 months, according to NHS Digital data from 2024.
  • In 2025, 45% of patients enrolled in community weight management programmes completed the full course, a rise from 38% in 2022.

Overview of NHS Weight Loss Services in 2026

The NHS continues to provide free weight loss services aimed at adults classified as overweight or obese. These services include behavioural support, dietary advice, physical activity programmes, and medication prescriptions where appropriate. The NHS prioritises evidence-based approaches and tailoring support to individual needs.

In 2026, the NHS focuses on early intervention, offering community-based programmes for those with a BMI over 25. These programmes aim to prevent progression to obesity and related health problems. They often involve group education sessions delivered over 12 to 16 weeks, combining nutritional guidance with physical activity and psychological support.

Specialist services, often referred to as Tier 3, are available for patients with a BMI of 30 or more, or 27.5 with comorbidities. These services are multidisciplinary, involving dietitians, psychologists, and physicians.

They may include more intensive behavioural therapy and access to medications such as liraglutide. For the highest risk patients — those with a BMI over 40 or 35 with severe health issues — bariatric surgery remains an option, typically following Tier 3 service involvement.

The NHS also supports digital and telephone-based interventions, which have grown in popularity since the pandemic. These alternatives can reduce waiting times and increase accessibility, especially in rural areas.

Mastheads

Weight Loss Support Options Compared

The NHS offers several routes to weight loss support, including:

  • Community Weight Management Programmes: These are free group sessions or one-to-one coaching focusing on diet, exercise, and lifestyle changes. They typically last 12–16 weeks and aim for a 5–10% weight loss target. Programmes often incorporate behaviour change techniques and peer support. In 2025, these programmes helped over 800,000 people across England alone.
  • Tier 3 Specialist Services: Multidisciplinary clinics provide comprehensive assessments and tailored plans, often lasting up to 26 weeks. These services include intensive behavioural therapy and medication where suitable. Referrals require a BMI of 30+ or 27.5+ with comorbidities. As of 2026, around 150,000 patients are enrolled in Tier 3 services annually across the UK.
  • Medication Prescriptions: Orlistat remains the most commonly prescribed NHS weight loss drug. It works by reducing fat absorption and is typically prescribed for up to 12 months. Liraglutide, a GLP-1 receptor agonist, is offered to patients with a BMI over 35 or 30 with comorbidities who haven't responded to diet and exercise alone. Its use has doubled since 2023, with approximately 50,000 patients currently receiving it on the NHS. The cost to the NHS per patient per year is estimated at £1,200, compared to £2,500–£3,000 in the private sector.
  • Bariatric Surgery: Reserved for patients with severe obesity (BMI over 40 or 35 with significant health problems), bariatric surgery is costly but effective. Waiting times vary but average around 9 months nationwide. About 12,000 procedures were carried out in NHS hospitals in 2025.

Patients often combine these options, beginning with community programmes, progressing to medication if needed, and surgery for eligible cases.

Regional Differences in NHS Weight Loss Services

Access and availability of NHS weight loss services vary across the UK regions:

  • London and South East England: These areas generally have shorter waiting times for community and Tier 3 services, averaging 5 to 7 weeks. They also have higher availability of specialist clinics and better integration with primary care.
  • North East and Wales: These regions report longer waiting times, often exceeding 10 weeks. There are fewer Tier 3 clinics per capita, leading to reduced access to specialist care.
  • Scotland: NHS Scotland offers similar weight management services, but with an emphasis on integrated care pathways and community health partnerships. Waiting times for specialist services average 8 weeks.
  • Northern Ireland: Access to weight loss medication is more restricted, with fewer patients receiving liraglutide prescriptions. Community programmes are available but with variable uptake.

Funding levels and local commissioning decisions influence these differences. Some areas have piloted digital weight loss programmes to improve reach and reduce delays.

Forecast for NHS Weight Loss Services Beyond 2026

The NHS will probably expand its weight loss support offerings in coming years in response to rising obesity rates. Plans include:

  • Introducing the GLP-1 oral medication foundayo into routine NHS prescribing following ongoing cost-effectiveness reviews. That could increase access to effective medication options beyond injectable liraglutide.
  • Increasing funding for community programmes to reduce waiting times and improve completion rates, aiming for a 50% completion rate by 2030.
  • Expanding digital and remote support services to reach underserved populations, particularly in rural and economically deprived areas.
  • Greater integration between primary care and specialist services to provide seamless patient journeys and earlier interventions.
  • Investment in training healthcare professionals in behavioural weight management techniques to boost capacity across the NHS.

Obesity remains a public health priority, with NHS England targeting a 5% reduction in adult obesity prevalence by 2030.

Achieving this will require sustained investment and collaboration across health and social care sectors.

The NHS remains the backbone of weight loss support in the UK in 2026, offering free programmes and medications to those who need them most. While some newer medications like GLP-1 pills await NHS approval and funding decisions, existing services provide vital routes to weight loss for over 1.5 million people yearly. Regional differences and waiting times persist, but ongoing expansions to digital and community-based support promise better access. With obesity rates still high, the NHS continues to prioritise weight management as a key element of improving public health.

This article was created with AI assistance.